Modulation of Gut Microbiota by Low Methoxyl Pectin Attenuates Type 1 Diabetes in Non-obese Diabetic Mice

Wu, Chengfei; Pan, Li-Long; Niu, Wenying; Fang, Xin; Liang, Wenjie; Li, Jiahong; Li, Hongli; Pan, Xiaohua; Chen, Wei; Zhang, Hao

Published in: Frontiers in Immunology

DOI: 10.3389/fimmu.2019.01733

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Modulation of Gut Microbiota by Low Methoxyl Pectin Attenuates Type 1 Diabetes in Non-obese Diabetic Mice

Chengfei Wu, Li-Long Pan, Wenying Niu, Xin Fang, Wenjie Liang, Jiahong Li, Hongli Li, Xiaohua Pan, Wei Chen, Hao Zhang, Jonathan R. T. Lakey, Birgitta Agerberth, Paul de Vos and Jia Sun

State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China; School of Food Science and Technology, Jiangnan University, Wuxi, China; School of Medicine, Jiangnan University, Wuxi, China; Department of Surgery, University of California, Irvine, Orange, CA, United States; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden; Division of Medical Biology, Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Intestinal homeostasis underpins the development of type 1 diabetes (T1D), and dietary manipulations to enhance intestinal homeostasis have been proposed to prevent T1D. The current study aimed to investigate the efficacy of supplementing a novel specific low-methoxyl pectin (LMP) dietary fiber in preventing T1D development. Female NOD mice were weaned onto control or 5% (wt/wt) LMP supplemented diets for up to 40 weeks of age, overt diabetes incidence and blood glucose were monitored. Then broad-spectrum antibiotics (ABX) treatment per os for 7 days followed by gut microbiota transfer was performed to demonstrate gut microbiota-dependent effects. Next-generation sequencing was used for analyzing the composition of microbiota in caecum. Concentration of short chain fatty acids were determined by GC-MS. The barrier reinforcing tight junction proteins zonula occludens-2 (ZO-2), claudin-1 and NOD like receptor protein 3 (NLRP3) inflammasome activation were determined by Western blot.

The proportion of CD25+ Foxp3+ CD4+ regulatory T cell (Foxp3+ Treg) in the pancreas, pancreatic and mesenteric lymph nodes was analyzed by flow cytometry. We found that LMP supplementation ameliorated T1D development in non-obese diabetic (NOD) mice, as evidenced by decreasing diabetes incidence and fasting glucose levels in LMP fed NOD mice. Further microbiota analysis revealed that LMP supplementation prevented T1D-associated caecal dysbiosis and selectively enriched caecal bacterial species to produce more SCFAs. The LMP-mediated microbial balance further enhanced caecal barrier function and shaped gut-pancreatic immune environment, as characterized by higher expression of tight junction proteins claudin-1, ZO-2 in caecum, increased Foxp3+ Treg population and decreased NLRP3 inflammasome activation in both caecum and pancreas. The microbiota-dependent beneficial effect of LMP on T1D was further proven by the fact that aberration of caecal microbiota by ABX treatment worsened T1D.
autoimmunity and could be restored with transfer of feces of LMP-fed NOD mice. These data demonstrate that this novel LMP limits T1D development by inducing caecal homeostasis to shape pancreatic immune environment. This finding opens a realistic option for gut microbiota manipulation and prevention of T1D in humans.

Keywords: low-methoxyl pectin, autoimmune diabetes, immunomodulation, gut microbiota, intestinal homeostasis

INTRODUCTION

Type 1 diabetes (T1D) is characterized by autoreactive T cell-mediated selective destruction of pancreatic beta-cells in genetically predisposed individuals (1). Despite its genetic attribution, accumulating evidence supports that intestinal homeostasis (2, 3), which involves the complex interaction between host immunity and commensal microbiota, is crucial for shaping the pancreatic immune environment and modulating the development of T1D (3–5).

Gut microbiota affects not only fermentation of food components and production of metabolites (5) but also influences host immune status and gut permeability, thus impacting autoimmunity processes during T1D (6). It has been proven that when the mutualistic relation between host immunity and the microbiota is compromised, alterations in bacteria function and diversity, a process called dysbiosis, may cause or contribute to T1D development (2, 3, 6, 7). For example, an increased abundance of Bacteroidetes at the phylum level and other types of gut dysbiosis has been regarded as a hallmark of T1D onset (8, 9). Gut dysbiosis is frequently associated with gut barrier dysfunction, resulting in increased gut permeability and translocation of diabetogenic proteins and macromolecular structures in T1D susceptible animal models and in humans to contribute to the disease development (4, 10, 11). The same studies showing the involvement of gut dysbiosis in T1D also demonstrate the flexibility of the gut microbial communities for manipulation by food components, which opens new venues to treat or prevent T1D (5, 9, 12).

One way to influence the microbiota is by providing them with dietary carbohydrate fibers that support microbiome diversity and growth of beneficial gut bacteria (12, 13), and to steer the aforementioned intestinal dysfunction (14–16). We have earlier shown that only dietary fibers with specific chemical compositions have these beneficial effects, while others are ineffective (16, 17). Finding dietary fibers with efficacy in preventing intestinal barrier dysfunction and dysbiosis is therefore highly needed as they might be effective in suppressing T1D development.

Originated from fruit and vegetables, pectin is a family of carbohydrates with a complex structure with an α-(1–4)-linked galacturonic acid polysaccharide backbone and can differ in degree of methyl esterification. Low-methoxyl pectin (LMP) refers to pectin in which the acid units in the backbone are methyl-esterified for <50%. Pectin has recently been shown to exhibit effects on intestinal microbiota and barrier function (14, 15). In addition, pectin or its fermentation products, such as acidic oligosaccharides in early life can result in the prevention of a number of allergic conditions and atopic dermatitis (18, 19). We have earlier shown that in the intestine, pectin, especially LMP, exert direct anti-inflammatory effects and reduce intestinal permeability (14, 15), and could therefore be instrumental in protecting against T1D.

In the present study, we investigated whether LMP supplementation influenced T1D development in non-obese diabetic (NOD) mice. Effects of LMP on diabetic incidence, aberration of pancreatic immune environment including NLRP3 inflammasome activation, and associated immune cell infiltration in NOD mice were studied. Also, effects on preventing T1D associated barrier dysfunction and dysbiosis were assessed (20). To determine the cause or consequence of LMP induced microbiota changes, microbiota was depleted by broad-spectrum antibiotics (ABX) treatment with or without LMP treated microbiota transferred to NOD mice with newly onset T1D, after which T1D development was followed.

MATERIALS AND METHODS

High Performance Gel Permeation Chromatography (HPGPC)

The molecular weight of LMP was analyzed by HPGPC with an ultrahydrogel TM Linear column (300 mm × 7.8 mmid × 2). A Waters 1525 system with a RI detector was used to perform the experiment. The mobile phase was 0.1 N NaNO₃ at a flow rate of 0.9 mL/min.

High Performance Anion Exchange Chromatography With Pulsed Amperometric Detection (HPAEC-PAD)

LMP hydrolysis was carried out by adding 20 drops of 2N trifluoroacetic acid into 1% (w/v) solution in DI water and heated at 95°C with shaking at 100 rpm in a shaking water bath for 6 h. The hydrolysates were filtered through 0.2 um filter and injected to an ICS-5000 system (Dionex, Sunnyvale, CA, USA) equipped with a Dionex CarboPac-PA20 analytical column (3 × 150 mm) (HPAEC-PAD) using gradient elution at a 0.5 mL/min flow rate.
Fourier Transform Infrared Spectroscopy (FTIR)
LMP powder was desiccated in a desiccator before analysis by placing on an attenuated total reflectance sampling accessory (Smart iTR, Thermo Fisher Scientific, Waltham, MA, USA) of an FTIR spectrometer (Nicolet 6700, Thermo Fisher Scientific) equipped with a single bounce diamond crystal. FTIR spectra of the sample were obtained by co-adding 64 scans at the resolution of 4 cm\(^{-1}\) in mid-infrared region (4,000–400 cm\(^{-1}\)).

Animals, Diets, and Blood Glucose Measurements
Female NOD/LtJ mice were purchased from Su Pu Si Biotechnology Co., Ltd (Suzhou, Jiangsu, China) and maintained in SPF environment at the Animal Housing Unit of Jiangnan University under a controlled temperature and a 12-h light/12-h dark cycle. All animal experiments were carried out according to protocols approved by the Institutional Animal Ethics Committee of Jiangnan University (IN. No 20150331-0410). Four-weeks old female NOD mice were fed with AIN-93G purified diets or supplemented with 5% (wt/wt) LMP for up to 40 weeks of age (n = 20). The dosage was chosen based on previous studies (14, 21, 22), and this dose is within the reported range of LMP for nutritional supplementation (3.3–15%) in literature (23–25). Fasting blood glucose levels were monitored at 40th and 11th week and determined with an Accu-chek glycosometer (

Histology
Pancreatic tissues were fixed, sectioned (5 µm thick) and stained with hematoxylin and eosin (H&E). The degree of insulitis was determined from multiple non-sequential slides from six individual mice. Slides were scanned by Pannorma 25× magnification. Mouse islets (30 per pancreata) were scored for the evaluation of insulitis and assigned a score by evaluating the degree of immune cell infiltration and categorized as follows: 0—no insulitis, 1—peri-insulitis, 2—insulitis with <50% infiltration of islets, 3—invasive insulitis with >50% in filtration of islets.

ABX Treatment and Microbiota Transfer (MT)
For ABX treatment, mice were given 1 g/L metronidazole, 0.5 g/L vancomycin, 1 g/L ampicillin and 1 g/L neomycin (Sigma-Aldrich, St. Louis, MO, USA) by daily oral gavage of 200 µL of the ABX solution (100% H\(_2\)O) for 7 days. In parallel with ABX treatment, mice were treated with 200 g/L amphotericin B of 100 µL in solution (100% H\(_2\)O) to avoid occasional overgrowth of Candida spp. Following 7-days ABX treatment, to suppress spontaneous gut microbial growth, the two groups of mice, NOD+ABX and NOD+LMP+ABX received ABX treatment every week until the mice were sacrificed.

For MT experiments, caecal content from eight LMP-fed or normal chow-fed SPF donor NOD mice was collected and immediately mix sufficiently in anaerobic chamber (diluted 1:10 in a 50% glycerol/PBS solution). Next, the solution was divided into aliquots and frozen in liquid nitrogen and thereafter stored at −80°C. At the day of inoculation, caecal microbiota-suspensions were further diluted 1:3 prior to oral gavage (~1–5 × 10\(^8\) cells per mice, as determined by THOMA counting-chamber). Dependent on the different treatments described above, groups of mice were designated as NOD, NOD + ABX, NOD + ABX + MT, NOD + LMP, NOD + LMP + ABX, and NOD + LMP + ABX + MT.

Western Blot
Tissue sample preparation and Western blotting were performed as previously described (16). Primary antibodies against NLRP3 (Cat: 15101), ASC (Cat: 67824), cleaved IL-1β (Cat: 63124), GAPDH (Cat: 5174), cleaved IL-18 (all from Cell Signaling Technology, Beverly, MA, USA), caspase-1-p20 (Cat: sc-1597), ZO-2 (Cat: sc-11448), claudin-1 (Cat: sc-17658), and occludin (Cat: sc-8144) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were applied.

Analysis of Short Chain Fatty Acids (SCFAs) and DNA Extraction for the Next-Generation Sequencing Analysis in Caecum
Caecal content samples (50 mg) were collected under sterile conditions and were stored in liquid nitrogen. Concentrations of SCFA were measured by GC coupled to the MS detector of GCMS-QP2010 (Shimadzu, Japan) as described previously (26). Bacterial genomic DNA from caecal content was extracted using FastDNA Spin kit for soil (MP Biomedicals, Santa Ana, California, USA) following the manufacturer's instructions. The V4 region of 16S rRNA was PCR-amplified using primers (sense: 5′-AYTGGGYDTAAAGNG-3′; antisense: 5′-TACNVGGGTATCTAATCC-3′). The PCR products were excised from a 1.5% agarose gel, purified by Gene Clean Turbo (MP Biomedicals, Santa Ana, CA, USA) and quantified by Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies, Carlsbad, USA), following the manufacturer’s instructions. Libraries were prepared using TruSeq DNA LT Sample Preparation Kit (Illumina, San Diego, USA) and sequenced for 500+7 cycles on Illumina MiSeq using the MiSeq Reagent Kit (500 cycles-PE).

Isolation of Immune Cells From Pancreas, Pancreatic Lymph Node (PLN), and Mesenteric Lymph Node (MLN) of NOD Mice
Immune cells were freshly prepared from pancreas, pancreatic lymph node (PLN) and mesenteric lymph node (MLN) as previously described (27) by passing the freshly isolated organs through a 70 µm nylon mesh. Cells were then washed with cold PBS and resuspended in PBS for staining.

Flow Cytometry
The single cells isolated from pancreas and lymph nodes were washed and resuspended in PBS. Surface staining was performed with the following mAbs: anti-CD45, -CD4, and -CD25 at
room temperature for 30 min. Detailed antibody information was shown in Supplementary Table 1. Cells were then fixed and permeabilized. Intracellular detection of Foxp3 was performed using anti-Foxp3 at 4°C for 50 min.

Statistical Analyses
Diabetes incidence was plotted according to the Kaplan-Meier method. Statistical significance was determined using a two-tailed Student’s t-test or when comparing multiple groups, one-way analysis of variance followed by Tukey’s post-hoc test. A p-value of <0.05 was considered statistical significant. Statistical analyses were carried out using GraphPad Prism 7 software (GraphPad, La Jolla, CA, USA).

RESULTS
Chemical Characterization of LMP
We first determined the chemical composition of the LMP. The molecular weight of LMP was 268.6 Kd as determined by HPGPC (Figure 1A). The composition of LMP was analyzed by HPAEC-PAD after acid hydrolysis and was found to be mainly composed of galacturonic acid (Figure 1B). The FTIR spectra of LMP

![Figure 1](image1.png)

**FIGURE 1 |** Chemical characterization of LMP. (A) The molecular weight of LMP was determined by HPGPC. (B) Chromatographic profile was obtained by HPAEC-PAD of monosaccharides of LMP. (C) FTIR profile of LMP.

![Figure 2](image2.png)

**FIGURE 2 |** LMP supplementation protects against T1D in NOD mice. (A) Diabetes incidence of NOD mice treated with (LMP) or without (normal chow) 5% LMP supplementation from 4 to 40 weeks of age, n = 20. (B) The fasting blood glucose of non-diabetic NOD mice at 40 weeks of age. (C) H&E staining of pancreatic islets from NOD mice at 40 weeks of age. Insulitis score was quantified. Scale bar, 100 µM. **p < 0.01 and ***p < 0.001.
consisted of characteristic peaks of polysaccharides (Figure 1C). The peak occurring in 3,432 cm\(^{-1}\) represents O-H stretching. The broad peak occurring from 1,100 to 1,070 cm\(^{-1}\) and from 1,070 to 1,043 cm\(^{-1}\) represents rhamose polygalaconic acid (Figure 1C).

**LMP Is Protective Against T1D in NOD Mice**

To examine the protective effects of LMP supplementation on T1D development, female NOD mice were weaned onto control (AIN-93G) or LMP-supplemented diets for up to 40-weeks age. LMP supplementation prevented T1D development, as 53.8% of the LMP-fed mice (7 mice) vs. all mice (20 mice) in the control group had developed overt diabetes (Figure 2A), and fasting glucose levels of LMP-fed mice were significantly lower than control NOD mice (Figure 2B). Accordantly, less immune cell infiltration and insulitis in pancreatic islets were observed in LMP-supplemented mice as indicated by histological examination and insulitis score (Figure 2C). Taken together, our results demonstrated that LMP supplementation protects against T1D in NOD mice.

**The Protective Effect of LMP on T1D Development Is Dependent on the Caecal Microbiota**

Dietary prebiotic fibers would preferentially expand beneficial bacteria to produce more SCFAs and thereby impart immunomodulatory effects (28). As LMP is predominantly fermented by gut microbiota in proximal large intestine (29), we firstly determined LMP fermentation derived SCFA in the caecum and colon, and found that acetate, propionate, butyrate and total SCFAs of LMP-supplemented mice significantly increased in caecum (Figure 3A) but not in colon (Figure 3B), demonstrating that most of the LMP is fermented by caecal microbiota before it reaches the colon to exert its effect.

In addition, dysbiosis is involved in T1D development in NOD mice (8, 16, 30). To further determine the cause or consequence of the LMP induced changes in microbiota, we performed two experiments: (i) We depleted the microbiota by ABX treatment and followed the diabetes incidence and (ii) we performed a transfer study of caecum microbiota of LMP-fed donor mice (MT) and normal chow-fed mice (NC) to control mice to confirm protective effects. NOD mice were treated by broad-spectrum ABX for 7 days to deplete gut microbiota, followed by 7-days MT treatment (Figure 4A). Incidence of diabetes was followed and effects of ABX treatment and MT were examined at 11-weeks age.

We found that ABX-treated mice exhibited increased blood glucose levels, and transfer of microbiota from LMP-fed donor mice (MT) afforded a better protective effect than those from normal chow-fed mice [MT(NC)] (Figure 4B). Accordantly, the incidence of T1D was lower in the NOD + LMP + ABX + MT mice compared with NOD + LMP + ABX + MT (NC) (Figure 4C). ABX treatment resulted in enhanced insulitis with increased immune cell infiltration in the pancreas (Figure 4D), upregulated proinflammatory (TNF-α) production and downregulated regulatory cytokine (TGF-β1) production (Figures 4E,F).

**LMP Prevents T1D-Associated Caecum Dysbiosis**

Next, we investigated whether LMP modulate diversity or specific bacterial species in caecum through 16s rDNA sequencing. As shown in Figure 5, LMP supplementation increased taxonomic units (OTU) (Figure 5A), the abundance and diversity of caecal microbiota composition (Figure 5B). By principal component analysis (PCA), we found that LMP-fed mice were distinctly separated from other three groups (Figure 5C). Besides, the taxonomic composition distribution histograms of each group were analyzed at phylum level (Figure 5D), and a significant change in the phyla *Firmicutes, TM7, Proteobacteria,* and class *Clostridia* composition was observed in the different treatment by linear discriminant analysis (Figure 5E). Specifically, LMP supplementation markedly enhanced the relative abundance of microbes from the phyla *Firmicutes, TM7, Proteobacteria* and class *Clostridia,* as well as ratio of the phylum *Firmicutes* vs. *Bacteroidetes,* in NOD+LMP mice (Figures 5F–J). Consistent with the higher microbial abundance and butyrate-producing *Clostridia,* more SCFAs in caecum were observed in LMP-fed mice (Figure 5K). In all aforementioned effects, ABX treatment reversed LMP-induced effects, which could be restored with

---

**FIGURE 3** | LMP increases acetate, propionate and butyrate production in the caecum of NOD mice. (A) Acetate, propionate, butyrate in caecal content were analyzed by GC-MS. (B) Acetate, propionate, butyrate in colonic content were analyzed by GC-MS. Bars represent means ± SEM; *p < 0.05; **p < 0.01, and ***p < 0.001.
transfer of feces of LMP-fed NOD mice. Taken together, our data clearly demonstrated that LMP administration prevents the T1D associated gut dysbiosis in NOD mice.

**LMP Prevents Barrier Dysfunction and Immune Imbalance in Caecum of NOD Mice**

As microbial-derived SCFAs promote gut barrier integrity and mucosal immune to reduce leakage of inflammatory mediators into systemic circulation, which protects against T1D (31). Next, we analyzed the LMP-modulated microbial balance and increased SCFAs on gut function. In the caecum, the expression of claudin-1 and ZO-2 were upregulated by LMP (Figure 6A). Accordantly, LMP supplementation significantly improved morphology of the caecum with improved barrier integrity and increased villus length in NOD mice (Figure 6B). Furthermore, downregulation of NLRP3, caspase-1-p20, cleaved-IL-1β, and IL-18 were observed in caecum of LMP-fed NOD mice compared to normal chow fed control mice (Figure 6C). Consistent with the beneficial effects on caecal function, increased frequencies of Foxp3+ Treg in MLN of caecum further confirmed the immunomodulatory effects of LMP (Figure 6D). However, the beneficial effects of LMP on caecum homeostasis was abolished by ABX treatment, since ABX treatment worsened caecal barrier dysfunction, morphology, and immune inflammatory response as evidenced by downregulated claudin-1 and ZO-2 expression, reduced villus length, upregulated NLRP3 inflammasome activation (NLRP3, ASC, caspase-1-p20, cleaved IL-1β, and IL-18), decreased Foxp3+ Treg frequencies in MLN. While transfer of caecal microbiota of LMP-fed NOD mice reversed ABX-induced caecal barrier dysfunction and immune dysregulation, indicating LMP-mediated microbial balance further stimulates gut homeostasis.

**LMP-Mediated Caecal Homeostasis Shapes Pancreatic Immune Environment in NOD Mice**

To verify the LMP-mediated caecal homeostasis on T1D prevention, we further detected the pancreatic immune responses in NOD mouse treated with LMP, ABX, and fecal...
FIGURE 5 | LMP prevents caecal dysbiosis of microbiota at onset of T1D. (A) The OTU Number among four groups of NOD mice after different treatments. (B) Alpha diversity indices among the four treated groups of NOD mice were displayed using boxplots. (C) Principal Component Analysis (PCA) analysis based on OTU abundance was shown. (D) The taxonomic composition distribution among four groups of phylum-level. (E) Cladograms generated by LEfSe indicate differences in taxa between different groups. (F–J) Relative abundance of Firmicutes (F), TM7 (G), Proteobacteria (H), Clostridia (I), and the ratio of Firmicutes/Bacteroidetes (J) were shown. (K) Acetate, propionate, butyrate in caecal content were analyzed by GC-MS. Bars represent means ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001, and ****p < 0.0001; Each point represents one mice.
microbial transplantation. Auto-immuno-attenuating effects of LMP were confirmed by the fact that frequencies of Foxp3+ Treg in both pancreas and PLN increased in NOD+LMP mice and decreased in ABX-treated NOD mice, but restored with the transfer of feces of LMP-fed NOD mice (Figures 7A,B). In addition, the modulatory effect of LMP on pancreatic immune responses during T1D was further confirmed by its suppressive effect on NLRP3 inflammasome activation (NLRP3, ASC, caspase-1 p20, cleaved IL-1β, and IL-18 expression) in the pancreas (Figure 7C). Meanwhile, ABX treatment promoted NLRP3 inflammasome activation in pancreas, and transfer of caecal microbiota of LMP-fed NOD mice reversed NLRP3 inflammasome activation. These results further demonstrated that LMP-mediated caecal homeostasis shapes pancreatic immune environment, thus preventing T1D development.
FIGURE 7 | LMP-mediated caecal homeostasis shapes pancreatic immune environment in NOD mice. (A) The frequency of CD25+ Foxp3+ cells in total CD4+ T cells in pancreas was determined by flow cytometry (n = 6). (B) The frequency of CD25+ Foxp3+ cells in total CD4+ T cells in PLN was determined by flow cytometry (n = 6). (C) Inflammasome pathway proteins, NLRP3, casp-1-p20, cleaved IL-1β, and cleaved IL-18 in pancreas were analyzed by Western blot analysis. *p < 0.05; **p < 0.01; ***p < 0.001, and ****p < 0.0001.
DISCUSSION

Here, we demonstrate that the previously unreported LMP supplementation reduces T1D incidence in NOD mice. The effect results from a positive impact on caecal microbiota, enhanced production of immune modulating bacterial products SCFA and improved intestinal integrity in the caecum. Induced gut homeostasis by LMP results in modulated gut-pancreatic autoimmune responses and hence protection against the development of T1D (Figure 8).

In comparison to previous findings from our group (16) and others (5) on mouse models of T1D, this study demonstrated that the protective effect of dietary fibers on the development of T1D was mediated by caecal homeostasis. This location of action in the large intestine may be attributed to the low esterified chemical composition of LMP that causes its rapid fermentation in the caecum. It has been suggested that the degree of esterification in the structure of pectin affects the fermentation location, product and health-promoting effects conferred (15, 29), and LMP supplementation in rat leading to more SCFAs in caecal contents (62µmol/g) than colonic contents (22µmol/g) (32), while the main fermentation region of high methoxylated pectins partly shifts from the caecum to the distal colon (33).

Intestinal dysbiosis with decreased microbiota diversity and loss of beneficial intestinal micro-organisms could lead to T1D (5, 21, 34, 35). For instance, a reduced ratio of Firmicutes to Bacteroidetes has been associated with and may contribute to the development of T1D, and microbial homeostatic maintenance has been considered as frontier strategy to treat T1D (3, 30).

Diversified microbiota composition and enriched beneficial intestinal bacteria with dietary supplementation of pectins have been demonstrated earlier (29, 36). Consistent with these earlier data, LMP supplementation increased α-diversity and the ratio of Firmicutes/Bacteroidetes in LMP-fed NOD mice. Additionally, LMP markedly increased the relative abundance of bacterial taxa including Firmicutes, TM7, Proteobacteria, Clostridia in NOD mice. Enriched Proteobacteria and TM7 phyla were found in mice fed gluten-free diet during pregnancy and lactation and their offspring with decreased incidence of diabetes and insulitis (37). Indigenous Clostridium species promoted gut and pancreatic Foxp3+ Treg cell accumulation (38, 39). Apparently, dietary pectin treatment significantly influences microbiota composition in NOD mice, which contributed to T1D prevention. Furthermore, experiments with ABX treatment followed by MT of caecal microbiota also confirmed that the protective effect of LMP on T1D was dependent on caecal microbiota. Notably, transferring caecal microbiota shaped by LMP into ABX-treated recipient mice fed on LMP conferred the most beneficial effects: restored caecal SCFA production, barrier function and modulating effects against T1D. When LMP-fed caecal microbiota was transferred to the ABX-treated mice fed on normal chow, only a trend of restoration was observed (Figures 4B,C), implying that LMP supplementation is essential to shape the “protective” caecal bacteria and that LMP-shaped caecal microbiota play a critical role in LMP-mediated protective effects. While ABX and MT experiments here have clearly demonstrated the role of caecal microbiota in LMP-mediated attenuation of T1D, future confirmatory experiments are warranted.

FIGURE 8 | LMP supplementation limits T1D by modulating gut homeostasis in NOD mice. LMP supplementation induces gut microbiota homeostasis to increase the production of SCFA in caecum and normalizes caecal barrier function by upregulating the expression of tight junction proteins, which results in decreased microbial antigen translocation, suppressed NLRP3 inflammasome activation and enhanced frequencies of Foxp3+ Treg in caecum and pancreas.
in germfree NOD mice may be more direct to establish its causal role.

Intriguingly, we observed higher increases in acetate, propionate and butyrate in caecum of NOD mice after LMP feeding. The production of SCFAs depend on the structure and chemical composition of dietary components and resident microbial composition (5, 29), higher increases in SCFAs production suggest that LMP may promote the growth and activity of SCFAs-producing bacteria in caecum. Indeed, Firmicutes phylum and Clostridia, which preferentially produce butyrate (5), were increased by LMP treatment. SCFAs production as a result of dietary supplementation provides a direct link to the associated beneficial effects. Specifically, enhanced butyrate production by dietary impact has been associated with modulatory effects on T1D (5, 40). Acetate, the most abundant SCFA in caecum of LMP-fed NOD mice, has also been clearly associated with modulating effects on T1D (5). Here, we provide the first evidence that diet enhanced propionate production was correlated with protection against T1D.

Foxp3+ Tregs, capable of suppressing proliferation and activation of autoimmune CD4 + and CD8+ effector T cells, are impaired in number and function during the development of T1D. They are the target cells in numerous studies to develop therapeutic strategies for T1D. Recently, the regulatory mechanisms of Foxp3+ Tregs have been unraveled in preventing over-activation of CD4+ or CD8+ T effector cells, that is through a variety of activities including cell-cell contact and soluble factors (41, 42). SCFAs elevate the number and function of induced Foxp3+ Treg cells in the colon and peripheral blood (43, 44). Furthermore, SCFAs also influence gene transcription in Foxp3+ Treg cells (45) via inhibition of histone-deacetylase (HDAC) activity. Consistent with these earlier data, significant increase of CD4+CD25+Foxp3+ T cells in pancreas, PLN and caecal MLN was observed in LMP-treated NOD mice, which explained its effects on delaying the onset of T1D. Whereas, our data clearly indicate caecal immune balance induced by LMP positively influenced pancreatic autoimmunity, the exact mechanism underlying caecum-pancreas axis that how Foxp3+ Tregs are induced from caecum and migrate or influence pancreatic immune environment is still unclear and deserve further investigations.

Recently, the role of NLRP3 inflammasome in T1D has been increasingly recognized (46, 47). Genetic ablation of NLRP3 protects mice from the development of T1D by suppressing T-cell activation and Th1 differentiation as well as by modulating pathogenic T-cell migration to the pancreatic islet. These effects of NLRP3 deficiency were mediated by modulating chemokine receptors on T cells and chemokine expression in the islets (47). In the settings of intestinal microenvironment, however, a dual role of NLRP3 inflammasome has been unraveled. While some studies showed a regulatory role of NLRP3 in maintaining immune tolerance and epithelial barrier integrity (48), others reported that overactivation of NLRP3 inflammasome under inflamed condition is associated with immune imbalance and detrimental effects (49). In this context, canonical vs. non-canonical NLRP3 inflammasome activation pathways associated with different downstream effector molecules are currently being investigated (49). Also different roles of NLRP3 in regulating intestinal homeostasis may be ascribed to different experimental models and settings. LPS induced activation of NLRP3 inflammasome was accompanied with intestinal epithelial dysfunction, which can be significantly inhibited by SCFAs (50). Dysfunction of intestinal epithelial barrier is suggested to be a crucial factor in the onset of intestinal and systemic autoimmune diseases, including T1D (51). In our observation, during the development of T1D with loss of intestinal homeostasis, LMP supplementation suppressed NLRP3 activation, which was associated with attenuated intestinal permeability, enhanced tight-junction protein expression and thus barrier function. Whereas, our data supported a positive association of canonical NLRP3 activation with the development of T1D and dysregulated intestinal homeostasis, molecular mechanisms to demonstrate any causative link remained to be explored.

In summary, we demonstrate that a novel dietary fiber, low esterified pectin, can ameliorate T1D through selective enrichment of specific microbiota species that produce SCFAs. This has specific effects on inflammasome activation, gut integrity and immune cell populations in the gut and pancreas, which prevent the development of T1D.

**DATA AVAILABILITY**

The datasets generated for this study can be found in NCBI PRJNA532521, PRJNA532521.

**ETHICS STATEMENT**

All animal experiments were carried out according to protocols approved by the Institutional Animal Ethics Committee of Jiangnan University (JN. No: 20150331-0410), in compliance with the recommendations of national and international guidelines for the Care and Use of Laboratory Animals, and were performed in accordance with the guidelines therein.

**AUTHOR CONTRIBUTIONS**

CW, WN, XF, WL, JL, and HL performed experiments and analyzed data. L-LP, WC, HZ, JL, BA, and PdV provided intellectual inputs, contributed to the data acquisition and interpreted experiments. XP, JS, PdV, and L-LP wrote the paper.

**FUNDING**

The work was supported by funds from the National Natural Science Foundation of China (Grant Nos: 91642114, 31570915, 81870439, and 81573420, National Youth 1000 Talents Plan), Jiangsu Province Recruitment Plan for High-level, Innovative and Entrepreneurial Talents, the Fundamental Research Funds for the Central Universities (Grant Nos: JUSRP51613A and
REFERENCES


SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2019.01733/full#supplementary-material


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Wu, Pan, Niu, Fang, Liang, Li, Li, Pan, Chen, Zhang, Lakey, Agerberth, de Vos and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.